Publication digest
View our publication digests to learn key findings on the use of CDK4/6 inhibitors for treatment of HR+/HER2−, node-positive, high-risk early breast cancer.
- Review data comparing clinical outcomes for various CDK4/6 inhibitors
- Learn the long-term benefits of adjuvant abemaciclib combined with endocrine therapy
- Consider the safety and tolerability profile of this combination therapy for breast cancer
A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer
Harbeck et al. A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer. Cancer. 2022;128: 2209-2223.
Despite the efficacy of current treatment approaches for hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) early breast cancer (EBC), approximately 20% of patients will still experience disease recurrence within the first 10 years1. Factors that increase this risk include large tumour size, tumour grade, nodal involvement, rate of proliferation (high Ki67 index) and vascular invasion2. Persistent risk for recurrence has driven investigation into the addition of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors to adjuvant endocrine therapy (ET)3. CDK4/6 inhibitors abemaciclib, palbociclib and ribociclib have shown efficacy in treatment of advanced HR+/HER2-breast cancer, however clinical studies investigating the efficacy in early breast cancer have demonstrated varying results, with only abemaciclib receiving approval for treatment4-7.
of interest
are looking at
saved
next event